Human influenza A and B viruses cause annual epidemics of the flu worldwide. Neuraminidase inhibitors such as Tamiflu are less effective in treating IBV than IAV. Monoclonal antibodies against IBV have been developed, but they have limited effectiveness. Given these limitations, researchers conducted studies using an in vivo plasmablast enrichment technique to isolate a human monoclonal antibody capable of neutralizing IBVs in vitro and that also protects against lethal IBV challenges in vivo.
Robust CD8+ memory T cells are important for protection against severe influenza disease caused by newly emerging strains.